Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.

Research in mice and humans is beginning to establish a link between the composition of microbes in the gut and immune responses to tumor cells, but the mechanisms are not yet clear.

The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.

Although the oral treatment seems to work, an analysis of the results from 12 clinical trials finds kids who got an immunotherapy have a greater rate of serious reactions.

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.

At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.

The Mount Sinai oncologist studies innate immune cells with the goal of designing novel immunotherapies, including cancer vaccines.

Researchers describe ways to study how cancer cells evade therapies that harness the immune system.